[go: up one dir, main page]

MXPA06013388A - Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. - Google Patents

Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.

Info

Publication number
MXPA06013388A
MXPA06013388A MXPA06013388A MXPA06013388A MXPA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A
Authority
MX
Mexico
Prior art keywords
lentiviral vector
vaccine
expression
applications
recombinant lentiviral
Prior art date
Application number
MXPA06013388A
Other languages
English (en)
Inventor
Philippe Despres
Pierre Charneau
Frederic Tangy
Marie-Pascale Frenkiel
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MXPA06013388A publication Critical patent/MXPA06013388A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Uso de un vector lentiviral recombinante que contiene un fragmento de polinucleotido que codifica al menos una proteina de un virus de la familia Flaviviridae o un peptido inmunogeno de al menos 8 aminoacidos de dicha proteina, para preparar una composicion farmaceutica dirigida a la prevencion y/o al tratamiento de una infeccion por Flaviviridae en especies sensibles.
MXPA06013388A 2004-05-17 2005-05-16 Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. MXPA06013388A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
PCT/IB2005/001753 WO2005111221A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Publications (1)

Publication Number Publication Date
MXPA06013388A true MXPA06013388A (es) 2007-06-19

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013388A MXPA06013388A (es) 2004-05-17 2005-05-16 Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.

Country Status (9)

Country Link
US (2) US20090214589A1 (es)
EP (2) EP1751291B1 (es)
JP (1) JP2008508863A (es)
CN (1) CN1981043B (es)
BR (1) BRPI0510016B8 (es)
CA (1) CA2564934C (es)
FR (1) FR2870126B1 (es)
MX (1) MXPA06013388A (es)
WO (1) WO2005111221A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1224314E (pt) 1999-10-12 2007-04-30 Pasteur Institut Adn triplex lentiviral e vectores e células recombinantes contendo adn triplex lentiviral.
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
CN102014952A (zh) * 2008-04-22 2011-04-13 赛托斯生物技术公司 用于治疗登革热的疫苗组合物和其用途
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP2603799A4 (en) * 2010-08-12 2014-02-12 Clontech Lab Inc SIDEFLOW ASSAYS FOR NON-DIAGNOSTIC ANALYSIS
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN108350037A (zh) 2015-11-09 2018-07-31 免疫设计股份有限公司 包含表达il-12的慢病毒载体的组合物及其使用方法
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334328D1 (de) * 1992-07-16 2010-06-10 Advanced Life Science Inst Inc Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
DK0904392T3 (da) 1996-10-17 2001-04-30 Oxford Biomedica Ltd Retrovirale vektorer
CA2315269A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
EP1045921A2 (en) * 1998-01-16 2000-10-25 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
EP1113777B1 (en) 1998-06-09 2007-01-10 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
ATE449858T1 (de) 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
PT1224314E (pt) 1999-10-12 2007-04-30 Pasteur Institut Adn triplex lentiviral e vectores e células recombinantes contendo adn triplex lentiviral.
EP1092780A1 (en) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Recombiant, replication defective CELO virus and CELO virus DNA
PT1383796E (pt) 2001-04-04 2009-07-21 Pasteur Institut Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
US20040037848A1 (en) 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
JP4718778B2 (ja) 2001-07-27 2011-07-06 ワイス・エルエルシー ウエストナイルワクチン
JP4580650B2 (ja) 2002-01-10 2010-11-17 アメリカ合衆国 西ナイルウイルスにより引き起こされる疾患を予防するために生ウイルスワクチン中に用いるための西ナイルウイルスおよびデングウイルスキメラの構築
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
DE10249594A1 (de) * 2002-10-24 2004-05-13 Jassoy, Christian, Dr. Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2456873A1 (en) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
EP1751291A1 (en) 2007-02-14
US20090214589A1 (en) 2009-08-27
FR2870126A1 (fr) 2005-11-18
EP1751291B1 (en) 2013-07-31
WO2005111221A1 (en) 2005-11-24
BRPI0510016A (pt) 2007-09-18
EP2371966A1 (en) 2011-10-05
FR2870126B1 (fr) 2009-07-17
CN1981043B (zh) 2010-06-09
US8716013B2 (en) 2014-05-06
CN1981043A (zh) 2007-06-13
CA2564934A1 (en) 2005-11-24
US20110206710A1 (en) 2011-08-25
EP2371966B1 (en) 2015-11-25
BRPI0510016B1 (pt) 2020-03-10
BRPI0510016B8 (pt) 2021-05-25
JP2008508863A (ja) 2008-03-27
CA2564934C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
NZ595063A (en) Polypeptides from neisseria meningitidis
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
NZ515936A (en) Antigenic Neisserial peptides
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
IL171991A0 (en) Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject
MXPA05005203A (es) Vacuna contra vhc.
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
EA200702079A1 (ru) Вакцина
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
FR2828405B1 (fr) Vaccin anti-coronavirus
PH12020551944A1 (en) Reverse peptide vaccine
WO2005056051A3 (en) Hepatitis b vaccines and compositions
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
WO2007101948A3 (fr) Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
NZ597470A (en) Therapeutic peptides, polypeptides ans nucleic acid sequences
NZ570708A (en) Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
WO2005016247A3 (en) Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon

Legal Events

Date Code Title Description
FG Grant or registration